Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. (3rd April 2019)

• Record Type: Journal Article
• Authors: Flannery, Kyle; Boyd, Marley; Black-Shinn, Jenny; Robert, Nicholas; Kamat, Ashish M
• Is Part Of: Future oncology. Volume 15:Number 12(2019)
• Page Start: 1323
• Page End: 1334
• Publication Date: 2019-04-03
• Subjects: bladder cancer -- cisplatin eligible -- patient outcomes -- real-world utilization -- treatment patterns; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0654
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC).Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016.Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7–14.6), and median OS for all 2L regimens was 9.4 months (8.2–11.1).Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.